Printer Friendly

Research and Markets: Emerging Cancer Vaccines Market to 2017 - Novel, First-In-Class Vaccines in Phase II and Phase III Pipeline to Shape the Future Cancer Vaccines Market.

DUBLIN -- Research and Markets (http://www.researchandmarkets.com/research/88badd/emerging_cancer_va) has announced the addition of the "Emerging Cancer Vaccines Market to 2017 - Novel, First-In-Class Vaccines in Phase II and Phase III Pipeline to Shape the Future Cancer Vaccines Market" report to their offering.

Emerging Cancer Vaccines Market to 2017 - Novel, First-In-Class Vaccines in Phase II and Phase III Pipeline to Shape the Future Cancer Vaccines Market, which provides insights into the global emerging cancer vaccines market and a market forecast until 2017. The report provides an in-depth analysis of the five therapeutic indications for which vaccines are available in the market or which have a promising vaccine in Phase III of their pipeline. In addition, the report also includes various types of cancer vaccine development and vaccine delivery methods along with a case study, advantages and disadvantages for each type, insights into the cancer vaccines R&D pipeline, SWOT profiles of the vaccine companies, and major Mergers and Acquisitions (M&A), deals and co-developments.

The Global Cancer Vaccines Market is Forecast to Grow at a CAGR of 21% between 2010 and 2017

Emerging Cancer Vaccines Market, Global, Revenue Forecasts ($m), 2006-2017 Source: GBI Research, Company Websites, Annual Reports, Press Releases, National Institutes of Health (NIH), National Cancer Institute (NCI), Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDC), World Health Organization (WHO), American Cancer Society, Globocan

The global cancer vaccines market is forecast to grow at a Compound Annual Growth Rate (CAGR) of 21% between 2010 and 2017, reaching revenues of $6.3 billion in 2017 from $1.7 billion in 2010.

The cancer vaccines market was occupied by three vaccines, namely, Gardasil from Merck, Cervarix from GlaxoSmithKline (GSK), and Provenge (sipuleucel-T) from Dendreon Corporation during the historical period 2006-2010. In the near future, cervical cancer, lung cancer, pancreatic cancer and melanoma are expected to witness the launch of cancer vaccines with better efficacy over the current treatment options. Promising Vaccines to be Launched in Melanoma, Lung and Pancreatic Cancer will Face Less Competition due to Absence of Marketed Vaccines

The global cancer vaccines market is presently dominated by cervical and prostate cancer vaccines. Cervical cancer is the only cancer indication to have two vaccines already available in the market and a promising vaccine in Phase III. The global cancer vaccine pipeline has a high percentage of Phase II and Phase III vaccines. The promising cancer vaccines that are first-in-class and have a novel mechanism of action will face less competition due to absence of marketed vaccines in lung cancer, pancreatic cancer and melanoma. Until 2017, cervical cancer, pancreatic cancer and melanoma are expected to have one vaccine launch each. Moreover, the pre-clinical and Phase I stages of cancer vaccine pipeline development have low percentages of vaccines. This indicates that until 2017 the global cancer vaccines market, excluding cervical and lung cancer, is not expected to face much competition until a second launch is targeted in the same indication as that of the first.

Companies Mentioned:

* Merck & Co., Inc.

* Merck Serono

* Amgen

* GlaxoSmithKline

* Dendreon

* KAEL-Gemvax

For more information visit http://www.researchandmarkets.com/research/88badd/emerging_cancer_va
COPYRIGHT 2011 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2011 Gale, Cengage Learning. All rights reserved.

 
Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Nov 8, 2011
Words:587
Previous Article:GoldSpot Media Unveils Open HTML5 Advertising Platform for Smartphones and Tablets.
Next Article:Hecla Reports 183% Increase in Third Quarter 2011 Net Income.
Topics:

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters